No Picture
News

Viracta Therapeutics Presents Preclinical Vecabrutinib Data in Oral and Poster Presentations at ASH 2021

SAN DIEGO: SAN DIEGO, Dec. 13, 2021 /PRNewswire/ — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the presentation of new preclinical data on vecabrutinib, a reversible inhibitor of Bruton’s tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK), in oral and poster presentations at the… Click here to view original post… […]

No Picture
News

HALOZYME APPOINTS NEW GENERAL COUNSEL

SAN DIEGO: SAN DIEGO, Dec. 13, 2021 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Mark Snyder has been appointed senior vice president, general counsel, chief compliance officer and corporate secretary, effective January 3, 2022. Mr. Snyder will succeed Masaru Matsuda, who is stepping down to pursue another… Click here to view original post… […]

No Picture
News

Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021

SAN DIEGO: SAN DIEGO, Dec. 13, 2021 /PRNewswire/ — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that final data from its Phase 1b/2 trial of Nana-val in relapsed/refractory (R/R) EBV+ lymphoma (VT3996-201) were presented in an oral presentation at the 2021 American Society… Click here to view original post… […]

No Picture
News

Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting

SAN DIEGO: SAN DIEGO, Dec. 13, 2021 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today reported interim results from its Phase 1/2 PRIME clinical trial of P-BCMA-101 for the… Click here to view original post… […]

No Picture
News

Wugen Presents New Preclinical Data Supporting the Safety and Efficacy of WU-CART-007 for T-Cell Malignancies at the 63rd Annual Society of Hematology (ASH) Annual Meeting

ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented new preclinical data supporting the safety and efficacy profile of WU-CART-007 for T-cell malignancies. Further, today’s data highlighted Wugen’s… Click here to view original post… […]

No Picture
News

MediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND

LA JOLLA, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Dr. Malath Makhay, Director, Scientific Affairs, presented the poster of MediciNova’s ongoing Phase… Click here to view original post… […]

No Picture
News

First Case of Community Acquired Omicron Variant in San Diego

Few places in the country are better equipped to detect new virus variants than San Diego, where researchers at UC San Diego School of Medicine and Scripps Research, working with county public health officials, health systems and others, collaborate to create a sort of viral early… Click here to view original post… […]

No Picture
News

Flagship on center stage: Axcella’s new CMO likens the biotech to ‘professional sports team’; Life after the FDA takes shape for Stephen Hahn as a chief executive

Margaret Koziel Margaret Koziel has bounced back and forth between academia and biotech throughout her career — and after 25 years, she has landed her first position as part of a biotech’s top brass. Koziel joined Axcella Therapeutics — founded by Flagship’s Noubar Afeyan, Geoffrey von… Click here to view original post… […]

No Picture
News

Oncolytics Biotech® Presents Positive Interim Safety Update from Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer Symposium

SAN DIEGO, Calif. and CALGARY, AB: – No safety concerns have been noted in any trial participants – Trial builds on prior clinical data demonstrating pelareorep’s ability to reverse immunosuppressive tumor microenvironments and upregulate PD-L1 expression in breast cancer SAN DIEGO, Calif. and CALGARY, AB, Dec. 10, 2021 /PRNewswire/ –… Click here to view original post… […]

No Picture
Uncategorized

Sr. Manager, Digital Marketing Operations, Service & Support – Remote – Thermo Fisher Scientific – San Diego, CA

7 to 10+ years of progressive experience in global and/or digital marketing, ideally for life science or biotechnology company. Master’s degree or MBA.From Thermo Fisher Scientific – Fri, 10 Dec 2021 00:16:15 GMT – View […]

No Picture
News

HALOZYME ANNOUNCES $750 MILLION THREE-YEAR SHARE REPURCHASE PROGRAM

SAN DIEGO: SAN DIEGO, Dec. 9, 2021 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its Board of Directors has approved a new share repurchase program effective immediately, which authorizes the Company to purchase up to $750 million of the Company’s outstanding common stock over the next three… Click here to view original post… […]

No Picture
News

Meet the ‘Heart Brothers’

This year’s 81 successful heart transplants to date continues a multi-year trend in which UC San Diego Health has performed four to nine times as many procedures annually as other local providers. So, it doesn’t… […]